XORTX Therapeutics Inc (XRTX) - Total Liabilities
Based on the latest financial reports, XORTX Therapeutics Inc (XRTX) has total liabilities worth CA$837.41K CAD (≈ $605.77K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See working capital to net assets of XORTX Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.
XORTX Therapeutics Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how XORTX Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see XRTX total asset value.
XORTX Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of XORTX Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Marston’s PLC
LSE:MARS
|
UK | GBX1.53 Billion |
|
Ridgetech, Inc.
NASDAQ:RDGT
|
USA | $28.25 Million |
|
Chinhung International Inc. Pfd. Series 2
KO:002787
|
Korea | ₩253.44 Billion |
|
Maxeon Solar Technologies Ltd
NASDAQ:MAXN
|
USA | $507.96 Million |
|
Prophecy International Holdings Ltd
AU:PRO
|
Australia | AU$15.82 Million |
|
Taiton Resources Ltd
AU:T88
|
Australia | AU$279.52K |
|
Enterprise Metals Ltd
AU:ENT
|
Australia | AU$301.91K |
Liability Composition Analysis (2018–2024)
This chart breaks down XORTX Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See XORTX Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how XORTX Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for XORTX Therapeutics Inc (2018–2024)
The table below shows the annual total liabilities of XORTX Therapeutics Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$757.99K ≈ $548.32K |
-8.23% |
| 2023-12-31 | CA$825.94K ≈ $597.47K |
-84.62% |
| 2022-12-31 | CA$5.37 Million ≈ $3.88 Million |
+1.33% |
| 2021-12-31 | CA$5.30 Million ≈ $3.83 Million |
+412.31% |
| 2020-12-31 | CA$1.03 Million ≈ $748.13K |
-20.43% |
| 2019-12-31 | CA$1.30 Million ≈ $940.18K |
+37.72% |
| 2018-12-31 | CA$943.70K ≈ $682.66K |
-- |
About XORTX Therapeutics Inc
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the … Read more